Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies

Cobalamin Seen As Broadly Applicable For Oral Delivery Of Many Large Molecule Drugs Now Administered By Injection

DALLAS, March 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin(TM) Oral Drug Delivery Technology.
 

Access previously reported that its novel Cobalamin-coated insulin containing nanoparticle formulations delivered orally provided a pharmacological response (lowering of blood glucose levels in animal models) equivalent to greater than 80% of that achieved by insulin delivered subcutaneously. The Company believes the substantial oral bioavailability found underscores the formulation's potential for clinical development and ultimate commercialization. Additionally, Access believes that its Cobalamin Oral Drug Delivery Technology has broad application to proteins, small molecule drugs, hormones, and potentially sRNAi therapeutics.
 

In addition to insulin, adaptation of this technology has provided a Cobalamin human growth hormone (HGH) formulation that has demonstrated good efficacy, represented by more than 25% improvement in weight gain, when given orally in an established animal model. Access continues moving its insulin and HGH products towards clinical development, while submitting additional patents surrounding both formulations.
 

"We remain excited about the potential of our Cobalamin oral drug delivery technology, and the positive data being generated," stated Jeff Davis, CEO of Access Pharmaceuticals, Inc.
 

Access' worldwide-exclusive patented Cobalamin technology utilizes the body's natural vitamin B12 oral uptake to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism. This technology platform provides Access with the ability to develop a number of different formulations with improved benefits for various disease applications.
 

"We have several ongoing discussions with other companies regarding the application of our oral drug delivery options for their promising new drugs. Additionally, we continue exploring ways to move this to a proof-of-concept human trial as quickly as possible," commented Phillip Wise, Access' Vice President of Business Development and Strategy.
 

About Access:
 

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
 

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
 

  Contact: Company                   
  ----------------                   
  Stephen B. Thompson                
  Vice President, Chief Financial Officer                       
  Access Pharmaceuticals, Inc.       
  (214) 905-5100

  Christine Berni
  Director of Investor Relations
  Access Pharmaceuticals, Inc.
  (212) 786-6208

  Contact: Investor Relations
  ---------------------------
  Donald C. Weinberger/Diana Bittner
  (media)
  Wolfe Axelrod Weinberger Assoc. LLC
  (212) 370-4500

Source: Access Pharmaceuticals, Inc.

CONTACT: Stephen B. Thompson, Vice President, Chief Financial Officer,
Access Pharmaceuticals, Inc., +1-214-905-5100; Christine Berni, Director of
Investor Relations, Access Pharmaceuticals, Inc., +1-212-786-6208; Donald C.
Weinberger or Diana Bittner, Wolfe Axelrod Weinberger Assoc. LLC,
+1-212-370-4500
 

Web Site: http://www.accesspharma.com/
 

Posted: March 2010

View comments

Hide
(web5)